Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey
Introduction: Atrial fibrillation (AF) is the most common arrhythmia with a prevalence that increases by aging. AF causes morbidity and mortality due to thromboembolic events. In developing countries, the use of new generation medications can be delayed. Objective: We evaluated nonvalvular AF patien...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2020-01-01
|
| Series: | International Journal of the Cardiovascular Academy |
| Subjects: | |
| Online Access: | http://www.ijcva.com/article.asp?issn=2405-8181;year=2020;volume=6;issue=2;spage=66;epage=69;aulast=Ozdemir |
| _version_ | 1797727559527432192 |
|---|---|
| author | Emre Ozdemir Ozgen Safak Sadik Volkan Emren Mehmet Serdar Bayata |
| author_facet | Emre Ozdemir Ozgen Safak Sadik Volkan Emren Mehmet Serdar Bayata |
| author_sort | Emre Ozdemir |
| collection | DOAJ |
| description | Introduction: Atrial fibrillation (AF) is the most common arrhythmia with a prevalence that increases by aging. AF causes morbidity and mortality due to thromboembolic events. In developing countries, the use of new generation medications can be delayed. Objective: We evaluated nonvalvular AF patients without effective oral anticoagulation (OAC) when non- vitamin K antagonists (NOACs) were mostly unavailable in Turkey before 2012–2013. The results were compared with what would happen if NOAC was available in use. Patients and Methods: Two-hundred and five patients in AF with adequate information were detected 123 of these patients were nonvalvular AF, (92 patients in these 123 ones were not taking OAC or on ineffective INR range) were included in the study. Results: Thirty-one (25.2%) of these patients were already on effective warfarin therapy. Ninety-two (74.8%) patients were not on warfarin therapy or on out of effective therapeutic range. About 52.2% of participants were female. The mean age was 70.62 ± 11.8 years. Eighteen (19.5%) patients had a recurrent stroke. Conclusion: OACs are recommended for patients with high stroke risk according to CHA2DS2-VASc score. OAC therapy significantly decreases mortality, morbidity, and also especially stroke risk. The only OAC therapy was warfarin over the decades until NOACs have been found. In our study, if NOACs could be available before 2012 in Turkey, 74.8% of our cohort would be under the effective anticoagulation and 19.5% of patients may have avoided from stroke. This is important for patients' lives and also for their costs. |
| first_indexed | 2024-03-12T11:01:30Z |
| format | Article |
| id | doaj.art-6f2f21e180d945ca928b23e265e67a47 |
| institution | Directory Open Access Journal |
| issn | 2405-8181 2405-819X |
| language | English |
| last_indexed | 2024-03-12T11:01:30Z |
| publishDate | 2020-01-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | International Journal of the Cardiovascular Academy |
| spelling | doaj.art-6f2f21e180d945ca928b23e265e67a472023-09-02T05:32:05ZengGalenos Publishing HouseInternational Journal of the Cardiovascular Academy2405-81812405-819X2020-01-0162666910.4103/IJCA.IJCA_61_19Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in TurkeyEmre OzdemirOzgen SafakSadik Volkan EmrenMehmet Serdar BayataIntroduction: Atrial fibrillation (AF) is the most common arrhythmia with a prevalence that increases by aging. AF causes morbidity and mortality due to thromboembolic events. In developing countries, the use of new generation medications can be delayed. Objective: We evaluated nonvalvular AF patients without effective oral anticoagulation (OAC) when non- vitamin K antagonists (NOACs) were mostly unavailable in Turkey before 2012–2013. The results were compared with what would happen if NOAC was available in use. Patients and Methods: Two-hundred and five patients in AF with adequate information were detected 123 of these patients were nonvalvular AF, (92 patients in these 123 ones were not taking OAC or on ineffective INR range) were included in the study. Results: Thirty-one (25.2%) of these patients were already on effective warfarin therapy. Ninety-two (74.8%) patients were not on warfarin therapy or on out of effective therapeutic range. About 52.2% of participants were female. The mean age was 70.62 ± 11.8 years. Eighteen (19.5%) patients had a recurrent stroke. Conclusion: OACs are recommended for patients with high stroke risk according to CHA2DS2-VASc score. OAC therapy significantly decreases mortality, morbidity, and also especially stroke risk. The only OAC therapy was warfarin over the decades until NOACs have been found. In our study, if NOACs could be available before 2012 in Turkey, 74.8% of our cohort would be under the effective anticoagulation and 19.5% of patients may have avoided from stroke. This is important for patients' lives and also for their costs.http://www.ijcva.com/article.asp?issn=2405-8181;year=2020;volume=6;issue=2;spage=66;epage=69;aulast=Ozdemiratrial fibrillationnonvalvular atrial fibrillationnovel oral anticoagulantswarfarinwarfarin |
| spellingShingle | Emre Ozdemir Ozgen Safak Sadik Volkan Emren Mehmet Serdar Bayata Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey International Journal of the Cardiovascular Academy atrial fibrillation nonvalvular atrial fibrillation novel oral anticoagulants warfarin warfarin |
| title | Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey |
| title_full | Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey |
| title_fullStr | Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey |
| title_full_unstemmed | Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey |
| title_short | Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey |
| title_sort | traditional warfarin coumadin therapy usage experience on nonvalvular atrial fibrillation before non vitamin k antagonists new oral anticoagulants era from a center in turkey |
| topic | atrial fibrillation nonvalvular atrial fibrillation novel oral anticoagulants warfarin warfarin |
| url | http://www.ijcva.com/article.asp?issn=2405-8181;year=2020;volume=6;issue=2;spage=66;epage=69;aulast=Ozdemir |
| work_keys_str_mv | AT emreozdemir traditionalwarfarincoumadintherapyusageexperienceonnonvalvularatrialfibrillationbeforenonvitaminkantagonistsneworalanticoagulantserafromacenterinturkey AT ozgensafak traditionalwarfarincoumadintherapyusageexperienceonnonvalvularatrialfibrillationbeforenonvitaminkantagonistsneworalanticoagulantserafromacenterinturkey AT sadikvolkanemren traditionalwarfarincoumadintherapyusageexperienceonnonvalvularatrialfibrillationbeforenonvitaminkantagonistsneworalanticoagulantserafromacenterinturkey AT mehmetserdarbayata traditionalwarfarincoumadintherapyusageexperienceonnonvalvularatrialfibrillationbeforenonvitaminkantagonistsneworalanticoagulantserafromacenterinturkey |